文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

新确诊HIV感染者是否应检测基线整合酶耐药?

Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?
PubMed 文献 · Clin Infect Dis · 2017-01-01

该研究用模型比较新确诊HIV感染者诊断时是否进行整合酶耐药(IR)检测两种策略的96周临床结局与成本效果。基线传播性INSTI耐药流行率估计为0.1%。结果显示IR检测临床结局更差且每人每年增加200美元成本,作者认为不应在治疗指南中推荐治疗前INSTI耐药评估。

要点

  • 新确诊HIV感染者诊断时常规IR检测预计结局更差且不具成本效果。
  • 除非DTG对INSTI-R病毒抑制率<20%或DRV/r的96周抑制率>92%,否则不做IR检测更优。
  • 传播性INSTI-R流行率高低不改变上述优选策略。

核心结论

  • 在新确诊HIV患者中,IR检测预计导致更差结局且不具成本效果,不应在治疗指南中推荐治疗前INSTI耐药评估。

研究设计与样本

  • 研究比较两种策略:不做IR检测 vs 在HIV诊断时做IR检测,比较96周临床结局与成本效果。
  • 基础病例的传播性INSTI耐药病毒流行率估计为0.1%。
  • 成本包括IR检测175美元与ART每年41100–44900美元,并对关键参数做敏感性分析。

主要发现

  • IR检测相比不做IR检测临床结局更差,且每人每年增加200美元成本。
  • 传播性INSTI-R病毒流行率不影响优选策略。
  • 除非DTG对INSTI-R病毒抑制率<20%或DRV/r的96周抑制率>92%,否则不做IR检测在临床上仍更优。
  • 若DRV/r方案生活质量劣于DTG方案,不做IR检测在更广参数范围内临床更优。

关键数值与推荐

  • 不做IR检测策略:所有患者基因型后启动以DTG为基础的ART,12周抑制率INSTI-S为90%、INSTI-R为35%。
  • 不做IR检测策略:12周未抑制者接受IR检测,若诊断为INSTI-R则换用以DRV/r为基础的ART。
  • 做IR检测策略:ART启动前诊断INSTI-S/INSTI-R,分别启动DTG或DRV/r为基础的方案。

临床怎么用

  • 对新确诊HIV感染者,不应常规在治疗前检测整合酶耐药以指导一线ART选择。

局限性

  • 研究为模型分析,结果依赖所设定的参数假设及敏感性分析范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend genotype resistance testing at diagnosis to guide initial selection of antiretroviral therapy (ART). Many standard resistance genotypes exclude testing for resistance to integrase inhibitors ("IR testing"), although this class of drugs is a component of most recommended first-line regimens. METHODS: We compared the 96-week clinical outcomes and cost-effectiveness of 2 strategies: no IR testing vs IR testing performed at human immunodeficiency virus (HIV) diagnosis. The base case prevalence of transmitted integrase strand transfer inhibitor (INSTI)-resistant (INSTI-R) virus is estimated at 0.1%. With no IR testing, all patients start dolutegravir (DTG)-based ART after genotype; 12-week suppression rates are 90% (INSTI-susceptible [INSTI-S] virus) and 35% (INSTI-R virus). Those not suppressed at 12 weeks undergo IR testing; if diagnosed with INSTI-R virus, they change to ritonavir-boosted darunavir (DRV/r)-based ART. With IR testing, all patients are diagnosed with INSTI-S/INSTI-R virus prior to ART initiation and start DTG- or DRV/r-based regimens, respectively. Costs include IR tests (175 US dollars [USD]) and ART (41100-44900 USD/year). We examined the impact of key parameters in sensitivity analyses. RESULTS: IR testing resulted in worse clinical outcomes compared to no IR testing and increased costs by 200 USD/person/year. Prevalence of transmitted INSTI-R virus did not affect the favored strategy. No IR testing remained clinically preferred unless DTG suppression of INSTI-R virus was <20% or 96-week DRV/r suppression was >92%. If quality of life was worse with DRV/r- than DTG-based ART, no IR testing was clinically preferred over an even broader range of parameters. CONCLUSIONS: In patients with newly diagnosed HIV, IR testing is projected to result in worse outcomes and is not cost-effective. Pretreatment assessment for INSTI resistance should not be recommended in treatment guidelines.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Koullias Y, Sax PE, Fields NF, et al. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus? Clin Infect Dis. 2017. PMID: 28605418. doi:10.1093/cid/cix542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。